Stock BRPA NRX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Real-time Estimate Cboe BZX
Other stock markets
 12:42:17 2024-04-29 EDT 		5-day change 1st Jan Change
3.525 USD -0.42% Intraday chart for NRx Pharmaceuticals, Inc. +21.66% -20.66%
04-18 NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq MT
04-18 Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
NRx Pharmaceuticals, Inc., Conversio Health, LLC and Nephron Pharmaceuticals Corporation Complete Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression
NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis
NRx Pharmaceuticals Says It Reached Nasdaq Listing Compliance
Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors
NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression
NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain
NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug Application for NRX-101 to Treat Chronic Pain
NRX Pharmaceuticals Signs Data Sharing Agreement to Support FDA Submission on Suicidal Bipolar Depression Therapy
NRx Pharmaceuticals, Inc. Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for Treatment of Suicidal Bipolar Depression
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BRPA Stock
  4. News NRx Pharmaceuticals, Inc.
  5. Other languages